Status:
ACTIVE_NOT_RECRUITING
Risk Stratification of COVID-19 Using Urine Biomarkers
Lead Sponsor:
National Center for Global Health and Medicine, Japan
Conditions:
Covid19
Urine
Eligibility:
All Genders
20+ years
Brief Summary
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and in infected patients, it produces symptoms which range from completely asymptomatic to...
Detailed Description
This study will conduct to elucidate the following clinical question; 1. if the single urinary biomarker or the combination of urinary biomarkers will clarify the risk of COVID-19 confirmed mild case...
Eligibility Criteria
Inclusion
- COVID-19 confirmed cases by qPCR exam or equivalent.
- Those who agreed to join this study
- Those who received treatment at NCGM, affiliated hospital and institute including accommodation facilities for observational purposes.
Exclusion
- Age less than 20
- Those who do not have smart phone (no personal contract)
- eGFR less than 30
- Any pre-existing illness with fever, weakness, or respiratory difficulties, Pregnancy or breastfeeding.
- Doctors' judgements to inappropriate for inclusion
Key Trial Info
Start Date :
September 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 25 2024
Estimated Enrollment :
964 Patients enrolled
Trial Details
Trial ID
NCT04681040
Start Date
September 15 2020
End Date
March 25 2024
Last Update
March 27 2024
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
MD Mount Sinai
Baltimore, Maryland, United States, 21215
2
Hospital das Clinicas Ribeirao Preto
Ribeirão Preto, São Paulo, Brazil
3
Danish National Biobank
Copenhagen, Denmark
4
Shonan General Hospital
Kamakura, Kanagawa, Japan, 247-8533